An Impartial Opinion Of ABT-263

0005), versus only 1.20 �� 0.33, 7 (P http://www.selleck.cn/products/Erlotinib-Hydrochloride.html were 313 �� 96 pg/mL, unchanged, and decreased (P http://www.selleckchem.com/products/ABT-263.html Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has been associated with increased arterial thrombosis. It is unknown whether rofecoxib is associated with venous thromboembolism (VTE). We investigated, using a systematic review, the association between rofecoxib and venous thrombosis. Methods: A search strategy was implemented in two electronic databases. We identified all English language http://www.selleckchem.com/products/MK-2206.html studies in which rofecoxib was compared with placebo, irrespective of the primary outcome of the study, for a duration greater than 3 months. Only placebo-controlled trials were included as other common comparators (e.g., NSAIDs) may have antithrombotic effects. Two reviewers assessed study eligibility, and data were extracted in a standardized manner using RefMan software. Quality of the studies was assessed according to pre-established criteria. Pooled incidence rates were calculated using a Poisson distribution. Results: The search strategy identified 1,339 papers of which 15 studies met inclusion criteria. In 15,160 patients allocated to rofecoxib (9,217 person-years follow-up), there were eight VTEs reported when compared with nine VTEs in 13,147 patients (9,092 person-years) allocated to placebo (relative risk 0.87, 95% CI = 0.29�C2.56; P = NS). The estimated incidence of VTE was 86.8 per 100,000 (95% CI = 37.5�C171.2) person-years with rofecoxib and 99.1 per 100,000 person-years with placebo (95% CI = 45.3�C188). This difference is statistically insignificant (P = 0.78). Conclusion: Our findings are limited by the relatively small number of events, although the contributing sample size of 28,307 subjects (18,309 person years) is reasonable. We are also unsure that all venous events were captured.